Lanadelumab and other plasma kallikrein inhibitors are being clinically deployed for prophylaxis of HAE attacks [4–6]: our platform may be applied to monitor the effect of the administration of such inhibitors in HAE patients. Here, KLK4 is linked to hereditary angioedema.